New long-term data show SHINGRIX continues to provide high ... - GSK
Apr 17, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for up to approximately 11 years …
New data show Shingrix can provide at least 10 years of ... - GSK
Oct 19, 2022 · GSK plc (LSE/NYSE: GSK) today announced positive interim results from the ZOSTER-049 extension study showing that overall Shingrix (Zoster Vaccine Recombinant, …
GSK says efficacy of its shingles vaccine remains high after years
Apr 17, 2024 · British drugmaker GSK said on Wednesday long-term data showed that its blockbuster shingles vaccine, Shingrix, had 79.7% efficacy in participants aged 50 years and …
GSK’s Shingrix new prefilled syringe presentation accepted for …
Jan 10, 2025 · Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q3 Results for 2024. …
GSK’s Shingrix shows to offer ten years of shingles protection in …
Oct 20, 2022 · GSK has reported positive interim data from the ZOSTER-049 extension study, where its recombinant, adjuvanted Zoster vaccine, Shingrix, showed to offer a minimum of ten …
Look out GSK, Pfizer and BioNTech are coming for Shingrix
3 days ago · GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects, with peak sales potential of almost $6 billion. Now, Pfizer and BioNTech are joining forces to try to …
GSK warns of lower 2024 vaccine sales after weaker RSV, shingles …
Oct 30, 2024 · GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the …
GSK presents significantly positive outcomes of its vaccine against ...
May 15, 2024 · GSK plc on Wednesday announced positive data from the phase III trial which followed participants for up to approximately 11 years following initial vaccination with Shingrix.
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Sep 20, 2024 · Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy (respiratory syncytial virus [RSV] vaccine, …
GSK’s shingles vaccine shown to maintain high protection in long …
Apr 19, 2024 · GSK has announced positive long-term phase 3 results for its shingles vaccine, Shingrix, in adults aged 50 years and above following initial vaccination over a decade prior.